Clinical trial
Deucravacitinib Post-marketing Surveillance in Patients With Psoriasis in Japan
NCT05633264 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Deucravacitinib Post-marketing Surveillance in Patients With Psoriasis in Japan
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 5, 2022
- Completion date
- May 28, 2025
- Enrollment
- 369 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.